ElevateBio
29 articles about ElevateBio
-
ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth
5/24/2023
ElevateBio, LLC announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by Matrix Capital Management, and joined by a leading group of new and existing investors.
-
The Massachusetts-based company has claimed the year’s largest fundraise so far and secured a powerhouse R&D partner in Novo Nordisk to develop gene editing medicines.
-
ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting Highlighting Optimization of Processes for Viral Vector Production
5/16/2023
ElevateBio, LLC today announced four poster presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting taking place May 16-20, 2023, in Los Angeles, CA.
-
ElevateBio Appoints Heidi L. Wagner, J.D., as Global Head of Government Affairs
3/7/2023
ElevateBio, LLC today announced that Heidi L. Wagner, J.D., will be joining as Global Head of Government Affairs.
-
Life Edit’s technology will combine with Moderna’s mRNA platform to develop in vivo gene editing therapeutics against thus far undisclosed challenging genetic diseases.
-
ElevateBio to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/5/2023
ElevateBio to Present at the 41 st Annual J.P. Morgan Healthcare Conference.
-
ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T's T Cell Therapy Programs Targeting Core Oncogenic Drivers
11/15/2022
ElevateBio, LLC and Affini-T Therapeutics, today announced a partnership to advance Affini-T's engineered TCR-T therapies focused on KRAS (Kirsten rat sarcoma viral oncogene homolog), one of the most prevalent oncogenic driver mutations in solid tumor cancers.
-
ElevateBio BaseCamp Unveils its LentiPeakTM Lentiviral Vector Platform
11/3/2022
ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced the unveiling of ElevateBio BaseCamp’s proprietary LentiPeakTM lentiviral vector platform.
-
ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene Therapy Innovation
8/25/2022
ElevateBio, LLC (ElevateBio) and the University of Pittsburgh today announced that they have entered into a long-term strategic partnership to accelerate the development of highly innovative cell and gene therapies.
-
ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines
8/23/2022
ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced that it has partnered with the California Institute for Regenerative Medicine (CIRM) to advance the discovery and development of regenerative medicine as part of CIRM’s Industry Alliance Program.
-
ElevateBio Announces the Formation of a New Company With George Daley, M.D., Ph.D., and Boston Children’s Hospital to Develop iPSC-Derived Allogeneic Immune Therapies
8/4/2022
ElevateBio, LLC announced that it has formed a new company co-founded by George Daley, M.D, Ph.D., and Boston Children’s Hospital to develop allogeneic immune cell therapies based on a novel platform that generates functionally mature immune cells from induced pluripotent stem cells.
-
ElevateBio Announces Jill M. Mooney, Ph.D., Joins as Senior Vice President of Research and Development
6/2/2022
ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced that Jill M. Mooney, Ph.D., has joined as Senior Vice President of Research and Development (R&D).
-
ElevateBio Announces Presentation on Lentiviral Vector Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
5/4/2022
ElevateBio, LLC today announced a poster presentation on ElevateBio BaseCamp’s lentiviral vector production platform at the upcoming American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19, 2022 in Washington, DC.
-
Boston-based Kelonia Therapeutics launched after a successful $50 million Series A round of financing, which will push its research efforts in genetic medicines for immunology and oncology.
-
A new report showed the increased funding in 2021 mirrors national data that show accelerated financing in support of new therapies for multiple diseases, driven by COVID-19 concerns.
-
ElevateBio Announces Andrew Sandford Joins as President of ElevateBio BaseCamp
1/19/2022
ElevateBio, LLC today announced that Andrew Sandford has joined as President of ElevateBio BaseCamp, Inc.
-
ElevateBio to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/6/2022
ElevateBio, LLC, a technology-driven company focused on powering transformative cell and gene therapies, today announced it will present at the J.P. Morgan 40th Annual Healthcare Conference to be held virtually January 10-13, 2022.
-
ElevateBio Announces Issuance of U.S. Patent Providing Protection for RNA-Guided Nucleases Identified through its Life Edit Gene Editing Platform
11/15/2021
ElevateBio, LLC (ElevateBio), a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment (PTA).
-
ElevateBio Supercharges Gene Editing and Therapeutic Product Development Capabilities Through Acquisition of Life Edit Therapeutics
10/27/2021
ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that it has acquired all of AgBiome Delta, LLC’s shares of Life Edit Therapeutics, Inc. Life Edit offers a powerful suite of gene editing technologies that have the potential for any genomic sequence of interest to be removed, added, or altered.
-
With the complete acquisition of Life Edit, ElevateBio will be able to integrate that company’s genome editing capabilities with its cell and gene therapies.